Chemical Biology Program
The Arvin Dar Lab
Research
Professor
The Dar laboratory explores cancer mechanisms and new approaches in chemical biology. Our research integrates genetics, biochemistry, structure, and small molecule discovery. Our primary goal is to develop tools that enable us to modulate cell signaling networks, allowing for in-depth mechanistic exploration of disease and potential therapeutic applications.
In our previous work, we successfully designed chemical switches and conformational modulators that selectively bind to specific targets of interest. By manipulating the conformational equilibrium, we can effectively influence the formation of specific states or complexes. Another area of research has been on molecular glues that operate at the interface of biomolecular complexes to regulate the assembly, lifetime, and fate of signal transduction events.
Overall, we are focused on the development of chemical tools and probes to target cancers driven by dysregulated enzymes, receptors, cellular communication pathways, and the tumor microenvironment.
Research Projects
Publications Highlights
People
Arvin Dar, PhD
Benno C. Schmidt Chair of Cancer Research
Professor
- Arvin Dar’s lab develops chemical tools and probes to explore disease mechanisms and the structural biology of cancer targets.
- PhD, University of Toronto, Toronto, Ontario
- [email protected]
- Email Address
- 212-639-8825
- Office Phone
Members
Lab Alumni
Lab Affiliations
Achievements
- Mark Foundation for Cancer Research ASPIRE Award
- Friedman Brain Institute Scholar
- Pershing Square Sohn Prize for Young Investigators (PSSCRA)
- Pew-Stewart Scholars for Cancer Research (Pew Foundation)
- Damon Runyon-Rachleff Innovation Award
Read more
- NIH Director’s New Innovator Award
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Arvin Dar discloses the following relationships and financial interests:
-
Nested Therapeutics
Equity; Intellectual Property Rights; Professional Services and Activities
-
Prometeo Therapeutics
Equity; Intellectual Property Rights; Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].